Vivos Therapeutics Inc. (NASDAQ: VVOS) completed a $2.25 million private placement with V-Co Investors 3 LLC, an affiliate of New Seneca Partners Inc., the company announced. The transaction closed on March 31, 2026.

The funding included the conversion of a previously announced $1.4 million bridge note, before accounting for an original issue discount. Vivos sold common stock, a pre-funded warrant, and two common stock purchase warrants with 2-year and 5-year terms, both exercisable at $1.09 per share. V-Co 3 paid $1.34 for each share of common stock, pre-funded warrant and associated warrants.

Since 2024, affiliates of Seneca have invested a total of $13.4 million in Vivos. The company plans to use the net proceeds for general working capital purposes.

Vivos operates as a medical device and healthcare services company focused on treating breathing-related sleep disorders, including obstructive sleep apnea. The company has been shifting toward a medical affiliation distribution model, highlighted by its 2025 acquisition of The Sleep Center of Nevada operating assets.

The company recently announced that physician-owned professional entities supported by its management services subsidiary in Nevada received in-network status with commercial health insurance payers and participating status with Medicare.

"Vivos is focused on executing on key immediate term initiatives, including optimizing its operations in Las Vegas and Detroit, onboarding large new practice relationships, closely managing expenses and rolling out additional diagnostic procedures," stated Michael Skaff, Managing Director of New Seneca Partners. The company aims to achieve breakeven operating cash flow by the end of 2026.

Additional details about the private placement were disclosed in a Form 8-K filing with the Securities and Exchange Commission on April 3, 2026.